

(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 963 999 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication

15.12.1999 Bulletin 1999 50

(21) Application number: 97941259.0

(22) Date of filing 26.09.1997

(51) Int. Cl.⁶ C07K 14/47, A61K 38/17

(86) International application number:

PCT/JP97/03442

(87) International publication number:

WO 98/14474 (09.04.1998 Gazette 1998/14)

(84) Designated Contracting States

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

(30) Priority 30.09.1996 JP 25943296

(71) Applicant:

KYOWA HAKKO KOGYO CO., LTD.
Chiyoda-ku, Tokyo 100 (JP)

(72) Inventors:

- SHIBATA, Kenji
Tama-shi, Tokyo 206 (JP)

• YAMASAKI, Motoo

Machida-shi, Tokyo 194 (JP)

• YOSHIDA, Tetsuo

Machida-shi, Tokyo 194 (JP)

• MIZUKAMI, Tamio

Machida-shi, Tokyo 194 (JP)

(74) Representative:

VOSSIUS & PARTNER

Siebertstrasse 4

81675 München (DE)

(54) E2F ACTIVITY INHIBITORY COMPOUNDS

(57) Compounds represented by the general formula (I): R^1-A-R^2 or pharmacologically acceptable salts thereof wherein R^1 represents (un)substituted alkanoyl, (un)substituted aroyl, (un)substituted heteroarylcarbonyl, (un)substituted alkoxycarbonyl, (un)substituted aryloxy carbonyl, (un)substituted heteroaryloxy carbonyl, or hydrogen, R^2 represents hydroxy, (un)substituted alkoxy or (un)substituted amino, and A represents a partial peptide sequence comprising at least 12 consecutive amino acid residues in the sequence of a dimer forming or DNA binding region of each member of E2F family.

Description

Technical Field

[0001] The present invention relates to a novel peptide useful as a therapeutic agent of diseases such as tumor and arteriosclerosis, for which cellular abnormal growth is responsible, by inhibiting the activity of a transcription factor E2F which regulates the transcription of gene groups involved in the progress of cell cycle to thereby suppress cell growth.

Background Art

[0002] E2F is a transcription factor of importance for the transcription of a great number of genes involved in the progress of cell cycle and serves as a target protein of tumor suppression gene product Rb [EMBO J., 9, 2179 (1990); Cell, 65, 1053 (1991)]. As proteins composing E2F, E2F family and DP family have been known. Up to now, five molecules of the E2F family, namely E2F 1 to 5 have been identified, while two molecules of the DP family, namely DP1 and 2, have also been identified. It has been believed that the out of control of the expression or activity of E2F is deeply involved in the carcinogenesis of a great number of cells [Science, 258, 424 (1992); Trends in Biological Chemistry, 19, 108 (1994)]. It has also been reported that the inhibition of the transcriptional activity of E2F can suppress the growth of smooth muscle cells, which works as the cause of arteriosclerosis [Proc. Natl. Acad. Sci. USA, 92, 5855 (1995)]. Thus, the substance suppressing the E2F activity is useful as a therapeutic agent of tumor or diseases involving the abnormal growth of smooth muscle cells or the like, such as arteriosclerosis. Additionally, the substance may also be effective widely for autoimmune diseases which are exacerbated due to the growth of synovial cell, such as chronic rheumatoid arthritis, or diseases occurring because of the abnormal growth of mesangium cell, such as nephropathy. As to E2F suppressing agents, nucleic acid based compounds have been known, including antisense RNA [Cancer Res., 54, 1402 (1994)] and decoy based on the E2F binding sequence DNA [Proc. Natl. Acad. Sci. USA, 92, 5855 (1995)]. However, no peptides have been known yet as such suppressing agents.

Disclosure of the Invention

[0003] In accordance with the present invention, it is provided a compound represented by the general formula (I)



(wherein R¹ represents substituted or unsubstituted alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroarylcabonyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aryloxy carbonyl, substituted or unsubstituted heteroaryloxy carbonyl or a hydrogen atom; R² represents hydroxy, substituted or unsubstituted alkoxy, or substituted or unsubstituted amino, and A represents a peptide sequence comprising a partial amino acid sequence having at least 12 continuous residues in the sequence of the dimerization region or DNA binding region of each E2F family)[simply referred to as "Compound I" hereinafter] or a pharmaceutically acceptable salt thereof. In accordance with the present invention, a pharmaceutical composition comprising the Compound (I) or a pharmaceutically acceptable salt thereof is provided.

[0004] In the definition of each group in the formula (I), the alkanoyl includes alkanoyl groups with 1 to 20 carbon atoms, such as formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, lauroyl, and icosanoyl.

[0005] The substituted alkanoyl has, the same or different, 1 to 3 substituents such as hydroxy, carboxyl, alicyclic alkyl, substituted or unsubstituted phenyl or fluorenyl.

[0006] Herein, the alicyclic alkyl includes alicyclic alkyl groups with 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

[0007] The substituted phenyl has, the same or different, 1 to 3 substituents such as alkyl, alkoxy, hydroxy, nitro, sulfo, cyano or halogen. The alkyl and the alkyl moiety of the alkoxy include alkyl groups with 1 to 20 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, heptyl, decyl, dodecyl, and icosyl, and the halogen includes each atom of fluorine, chlorine, bromine and iodine.

[0008] The aryl moiety of the aroyl and the aryloxy carbonyl includes e.g. phenyl and naphthyl. Each of the substituted aroyl and the substituted aryloxy carbonyl has, the same or different, 1 to 3 substituents such as alkyl, alkoxy, hydroxy, nitro, sulfo, or halogen. The alkyl and the alkyl moiety of the alkoxy and the halogen have the same meanings as defined above, respectively.

[0009] The heteroaryl moiety of the heteroarylcabonyl and the heteroaryloxy carbonyl includes e.g. furyl, thienyl, pyridyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, indolyl, quinolyl, isquinolyl, and quinazolyl. Each of the substituted heteroarylcabonyl and the substituted heteroaryloxy carbonyl has the same substituents as defined for the


substituents of the substituted aryl.

[0010] The alkyl moiety of the alkoxycarbonyl and the alkoxy means the same as defined above. The substituents of the substituted alkoxycarbonyl and the substituted alkoxy include e.g. hydroxy, carboxy, carbamoyl, alicyclic alkyl, substituted or unsubstituted phenyl and fluorenyl. The alicyclic alkyl and the substituent of the substituted phenyl mean the same as defined above, respectively.


[0011] The substituted amino has, the same or different, 1 to 2 substituents such as substituted or unsubstituted alkyl, or substituted or unsubstituted aryl. The alkyl and the aryl have individually the same meanings as defined above. The substituents of the substituted alkyl include e.g. hydroxy, carboxy, carbamoyl, alicyclic alkyl and a phenyl group. The alicyclic alkyl has the same meaning as defined above. The substituted aryl has, the same or different, 1 to 3 substituents such as alkyl, alkoxy, hydroxy, nitro, sulfo or halogen. The alkyl and the alkyl moiety of the alkoxy, and the halogen have the same meanings as defined above, respectively.

[0012] In accordance with the present invention, the term "E2F" means a protein which binds to the E2F binding sequence in DNA and influences the promoter activity around the sequence. E2F is composed of the E2F family and DP family, and each family has a dimerization region and a DNA binding region. The sequences of the dimerization region and DNA binding region in each family of E2F are described in Cell, 70, 337 (1992), Cell, 70, 351 (1992), Mol. Cell Biol., 13, 7802 (1993), Mol. Cell Biol., 13, 7813 (1993), Genes and Dev., 8, 2680 (1994), Genes and Dev., 8, 2665 (1994), Proc. Natl. Acad. Sci. USA, 92, 2403 (1995), Nature, 362, 83 (1993), Mol. Cell Biol., 15, 2536 (1995) and the like.

[0013] The peptide sequence comprising a partial amino acid sequence having at least 12 continuous residues in the sequence of the dimerization region of the E2F includes e.g. a sequence represented by the general formula (Ia).




(wherein "n's" in individual amino acid residues are the same or different, and represent 0 or 1, X^1 , X^5 , X^{27} and X^{28} are the same or different, representing Leu or Ile, X^2 represents Asn or Lys, X^3 represents Trp, Lys, Leu, Ala or Glu, X^4 represents Ala or Ser, X^5 represents Glu, Asp or Asn, X^7 represents Val, Thr or Arg, X^9 represents Lys, Asp, Ala or His, X^{25} represents Gln, His, Gly, Asp or Asn, and X^{29} represents Ala, Arg, Lys or Glu), and a sequence represented by the general formula (Ib):



(wherein "m's" in individual amino acid residues are the same or different, and represent 0 or 1, Y^1 represents Asn, Thr, Ala or Tyr, Y^2 represents Glu or Asp, Y^3 represents Ser or Asn, Y^5 represents Ala or Asn, Y^9 represents Tyr or Cys, Y^{25} represents Lys or Glu, Y^{27} represents Met or Ile, and Y^{29} represents Ile or Val).

[0014] The peptide sequence comprising a partial amino acid sequence having at least 12 continuous residues in the sequence of the DNA binding region of the E2F includes e.g. a sequence represented by the general formula (Ic),



(Ic)

(wherein "p's" in individual amino acid residues are the same or different, and represent 0 or 1, Z¹ represents Ala, Phe or Pro; Z² represents Arg, Lys or Gln; Z³, Z⁵ and Z⁷ are the same or different, representing Gly or Pro; Z⁴ represents Arg, Lys, Met or Pro; Z⁶ represents Gly, Cys, Ala or Gln; Z⁸ represents Ala, Arg or Glu; Z⁹ represents Ala, Ile or Gln; Z¹⁰ represents Ala, Gly or Arg; Z¹¹ represents Leu, Val or Pro; Z¹² represents Asp, Arg or Gln; Z¹³ represents Gly, Ser, Ala or Pro; Z¹⁴ represents Leu or Pro; Z¹⁵ represents Asp, His or Pro; Z¹⁶ represents Ser or Pro; Z¹⁷ represents Gln or Lys; Z¹⁸ represents Gly, Thr or Leu; Z¹⁹ represents Gly, Pro or Val; Z²⁰ represents Gly or Lys; Z²¹ represents Ala or Ser; Z²² represents Gly or Ser; Z²³ represents Gly, Glu or Thr; Z²⁴ represents Arg, Lys, Ser or Pro; Z²⁵ represents Ser or Thr; Z²⁶ represents His or Tyr; Z²⁸ represents Asp or Glu; Z²⁹ and Z³⁰ are the same or different, representing Lys or Thr; Z³¹ represents Gly or Asn; Z³² represents Leu or Thr; Z³³ represents Arg or Lys; Z³⁴ represents Ile, Leu or Val; and Z⁴⁰ represents Glu, Gln, Ser or Tyr)

[0015] The pharmaceutically acceptable salt of the Compound (I) includes acid addition salts, metal salts, organic base addition salts and the like. The acid addition salts include inorganic salts such as hydrochloride, sulfate and phosphate, and organic salts such as acetate, maleate, fumarate, tartrate, and citrate. The metal salts include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminium salt, zinc salt and the like. The organic base addition salts include salts of primary amines such as methylamine, ethylamine and aniline; secondary amines such as dimethylamine, diethylamine, pyrrolidine, piperidine, morpholine and piperazine; and tertiary amines such as trimethylamine, triethylamine, N,N-dimethylaniline and pyridine, and ammonium salts.

[0016] The present invention will now be described in detail hereinbelow.

[0017] The abbreviations of amino acids and the protective groups thereof follow the recommendations by IUPAC-IUB Joint Commission on Biochemical Nomenclature [Eur. J. Biochem., 138, 9 (1984)].

[0018] The following abbreviations represent the following corresponding amino acids and protective groups thereof, unless otherwise stated.

Gly,	Glycine
Ala,	L-Alanine
50 Thr,	L-Threonine
Asp,	L-Aspartic acid
Asn,	L-Asparagine
Asx,	L-Aspartic acid or L-asparagine
Glu,	L-Glutamic acid
55 Gln,	L-Glutamine
Glx,	L-Glutamic acid or L-glutamine
Trp,	L-Tryptophan
Val,	L-Valine

Leu	L-Leucine
Ser	L-Serine
Met	L-Methionine
Ile	L-Isoleucine
5 Phe	L-Phenylalanine
Tyr	L-Tyrosine
Lys	L-Lysine
Arg	L-Arginine
His	L-Histidine
10 Pro	L-Proline
Fmos	9-Fluorenylmethyloxycarbonyl
t-Bu	t-Butyl
Trt	Trityl
Pmc	2,2,5,7,8-Pentamethylchroman-6-sulfonyl
15 Boc	t-Butyloxycarbonyl
Ac	Acetyl

[0019] The following abbreviations represent the corresponding side-chain-protected amino acids as follows

20	Fmoc-Asp(Ot-Bu)-OH; N ^H -9-Fluorenylmethyloxycarbonyl-L-aspartic acid β-t-butylester
	Fmoc-Glu(Ot-Bu)-OH; N ^H -9-Fluorenylmethyloxycarbonyl-L-glutamic acid β-t-butylester
	Fmoc-Thr(Ot-Bu)-OH; N ^H -9-Fluorenylmethyloxycarbonyl-O-t-butyl-L-threonine
	Fmoc-Ser(t-Bu)-OH; N ^H -9-Fluorenylmethyloxycarbonyl-O-t-butyl-L-serine
	Fmoc-Tyr(t-Bu)-OH; N ^H -9-Fluorenylmethyloxycarbonyl-O-t-butyl-L-tyrosine
25	Fmoc-Lys(Boc)-OH; N ^H -9-Fluorenylmethyloxycarbonyl-N ^H -t-butyloxycarbonyl-L-lysine
	Fmoc-Asn(Trt)-OH; N ^H -9-Fluorenylmethyloxycarbonyl-N ^H -trityl-L-asparagine
	Fmoc-Gln(Trt)-OH; N ^H -9-Fluorenylmethyloxycarbonyl-N ^H -trityl-L-glutamine
	Fmoc-Arg(Pmc)-OH; N ^H -9-Fluorenylmethyloxycarbonyl-N ^H -2,2,5,7,8-pentamethylchroman-6-sulfonyl-L-arginine
	Fmoc-His(Trt)-OH; N ^H -9-Fluorenylmethyloxycarbonyl-N ^H -trityl-L-glutamine
30	Fmoc-Trp(Boc)-OH; N ^H -9-Fluorenylmethyloxycarbonyl-N ^H -t-butyloxycarbonyl-L-tryptophane

[0020] The following abbreviations represent the corresponding reaction solvents and reaction reagents and the like as follows

35	PyBOP; Benzotriazol-1-yloxytrispyrrolidinophosphonium hexafluorophosphate
	HOBt; 1-Hydroxybenzotriazole
	NMM; N-Methylmorpholine
	DMF; N,N-Dimethylformamide
	TFA; Trifluoroacetic acid
40	HBTU; 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
	DIEA; N,N-Diisopropylethylamine
	NMP; N-Methylpyrrolidone

[0021] The method for producing the Compound (I) will now be described below.

45 [0022] The Compound (I) can be synthesized by general liquid phase or solid phase peptide synthetic methods (Fundamentals and Experiments of Peptide Synthesis, Nobuo Izumiya et al., Maruzen (1985)) or a combination thereof. Furthermore, an automatic peptide synthesizer may be used. The peptide synthesis on a commercially available peptide synthesizer, e.g. a peptide synthesizer manufactured by Shimadzu Corporation, a peptide synthesizer manufactured by Applied BioSystems Inc., USA (ABI Inc.), and a peptide synthesizer manufactured by Advanced ChemTech Inc., USA

50 (ACT Inc.) can be done by using N^H-9-fluorenylmethyloxycarbonyl amino acids or N^H-t-butyloxycarbonyl amino acids with an appropriately protected side chain, according to the synthetic programs for the individual peptide synthesizers.

[0023] The protected amino acid as the starting materials of the Compound (I) and carrier resin can be available from ABI Inc., Shimadzu Corporation, Kokusan Chemical Works Co., Ltd., Nova Biochem Co., Watanabe Chemical Industries, Ltd., ACT Inc. or Peptide Institute Inc.

55 [0024] The Compound (I) thus obtained can be purified by high-performance liquid chromatography (referred to as HPLC hereinbelow) by using reverse-phase silica gel columns such as C-4, C-8 or C-18 type, column chromatography such as gel filtration with partition resin, adsorption resin, ion exchange resin, silica gel, chemically modified silica gel, reverse-phase silica gel, alumina, diatomaceous earth or magnesium silicate, or thin-layer chromatography.

[0025] The pharmaceutically acceptable salt of the Compound (I) can be obtained in a conventional manner. More specifically, the acid addition salt or organic base addition salt of the Compound (I) can be obtained by dissolving the Compound (I) in an aqueous solution of an acid or an organic base corresponding thereto and then freeze-drying the solution. The metal salt of the Compound (I) can be obtained by dissolving the Compound (I) in an aqueous solution containing the corresponding metal ion and purifying the solution by gel filtration or by HPLC.

[0026] Specific examples of the Compound (I) are shown in Table 1. Specific examples of the compound being represented by the general formula (I) having the amino acid sequence represented by the general formula (Ia) include compounds represented by Sequence ID Nos 1, 2 and 20, which are referred to as Compounds Ia-1, Ia-2 and Ia-3, respectively. Specific examples of the compound being represented by the general formula (I) having the amino acid sequence represented by the general formula (Ib) include compounds represented by Sequence ID Nos 3, 4 and 21, which are referred to as Compounds Ib-1, Ib-2 and Ib-3, respectively. Specific examples of the compound being represented by the general formula (I) having the amino acid sequence represented by the general formula (Ic) include a compound represented by SEQ ID No 5, which is referred to as Compound Ic-1.

Table 1

Compounds	Sequences
Ia-1	Ac-Leu-Asn-Trip-Ala-Ala-Glu-Val-Leu-Lys-Val-Gln-Lys-Arg-Arg-Ile-Tyr-Asp-Ile-Thr-Asn-Val-Leu-Glu-Gly-Ile-Gln-Leu-Ile-Ala-NH ₂ (SEQ ID No 1)
Ia-2	Ac-Val-Leu-Lys-Val-Gln-Lys-Arg-Arg-Ile-Tyr-Asp-Ile-Thr-Asn-Val-NH ₂ (SEQ ID No 2)
Ia-3	La-Leu-Asn-Trip-Ala-Ala-Glu-Val-Leu-Lys-Val-Gln-Lys-Arg-Arg-Ile-Tyr-Asp-Ile-Thr-Asn-Val-Leu-Glu-Gly-Ile-Gln-Leu-Ile-Ala-NH ₂ (SEQ ID No 20)
Ib-1	Ac-Asn-Glu-Ser-Ala-Tyr-Asp-Gln-Lys-Asn-Ile-Arg-Arg-Arg-Val-Tyr-Asp-Ala-Leu-Asn-Val-Leu-Met-Ala-Met-Asn-Ile-Ile-Ser-NH ₂ (SEQ ID No 3)
Ib-2	Ac-Ile-Arg-Arg-Arg-Val-Tyr-Asp-Ala-Leu-Asn-Val-Leu-Met-Ala-Met-NH ₂ (SEQ ID No 4)
Ib-3	La-Asn-Glu-Ser-Ala-Tyr-Asp-Gln-Lys-Asn-Ile-Arg-Arg-Arg-Val-Tyr-Asp-Ala-Leu-Asn-Val-Leu-Met-Ala-Met-Asn-Ile-Ile-Ser-NH ₂ (SEQ ID No 21)
Ic-1	Ac-Ala-Arg-Gly-Arg-Gly-Arg-His-Pro-Gly-Lys-Gly-Val-Lys-Ser-Pro-Gly-Glu-Arg-Ser-Arg-Tyr-Glu-Thr-Ser-Leu-Asn-Leu-Thr-Thr-Lys-Arg-Phe-Leu-Glu-Leu-NH ₂ (SEQ ID No 5)

[0027] In the table, Ac represents an acetyl group, and La represents a lauroyl group.

[0028] The biological activity of the Compound (I) is now described in test examples.

Test Example 1

Assay of E2F-DNA binding-inhibiting activity by gel shift assay (1-1) Expression of a fusion protein of E2F-1 and DP-1 in Escherichia coli

[0029] So as to assay the activity to inhibit E2F-DNA binding, a fusion protein of glutathione-S-transferase (abbreviated as GST hereinafter) with the genes of human E2F-1 [Cell, 70, 337 (1992), Cell, 70, 351 (1992)] and human DP-1 [Genes Dev., 7, 1850 (1993)] was prepared.

[0030] Firstly, gene sequences carrying the DNA binding regions and dimerization regions of human E2F-1 and DP-1 were individually obtained by RT-PCR [Reverse Transcription Polymerase Chain Reaction, PCR Technology, Erlich, H.A., ed., p.89-97, Stockton Press (1989)].

[0031] An expression plasmid for E2F-1 was constructed by the following method. By AGPC method [Acid Guanidium Thiocyanate-Phenol Chloroform, Anal. Biochem., 162, 156 (1987)], RNA was prepared from a human B cell line Jijoye (ATCC CCL87), which was then subjected to reverse transcription by using a kit manufactured by GIBCO-BRL, namely Super Script II kit, to prepare the cDNA. From the cDNA was recovered an objective cDNA fragment, by dividing the human E2F-1 cDNA into two regions by using the following two pairs of the combinations of oligonucleotide primers:

5'-AGAGAGAAGCTTAAAGCGTCATGGCCTTGCGCGGGG-3' (38-mer, SEQ ID No 6) and
 5'-TTCTGCACCTTCAGCAGCTCGGCAGC-3' (26-mer, SEQ ID No 7) [N terminus], as well as
 5'-ACCAAGCGCTTCCTGGAAGCTGCTGAG-3' (26-mer, SEQ ID No 8) and
 5'-GGAAACCTCGGTACCTCGAAGCCCTG-3' (26-mer, SEQ ID No 9) [C terminus].

amplifying the two regions by using AmpliTaqTM Taq polymerase and DNA thermal cycler 480 [Perkin Elmer Cetus Co.] according to PCR (polymerase chain reaction) [Science, 239, 487 (1988)] and ligating the resulting two regions by using an inner Sall cleavage site. The resulting cDNA was cleaved with RsaI, to recover an RsaI (431)-RsaI(815) fragment [numerical figures in parentheses correspond to the base numbers in Cell, 70, 337 (1992)] of 338 base pairs. The DNA fragment was inserted into the SmaI cleavage site of plasmid pGEX-5X [manufactured by Pharmacia Co.] inserted with the N terminal region of GST downstream of the Tac promoter, to recover plasmid pGST-E2F-1 expressing a fusion protein of a part of human E2F-1 (101-st to 227-th amino acid residues from the N terminus) and GST

[0032] An expression plasmid for DP-1 was constructed by the following method. By the same method as described above, RNA and cDNA were prepared from a human B cell line DND-39 (Fujizaki Cell Center, Hayashibara Biochemical Research Institute). From the cDNA was amplified a DNA fragment carrying a part of the human DP-1 cDNA, by PCR with the following two oligonucleotide primers individually having BamHI and EcoRI cleavage sequences at 5' terminus:

5'-CCACGGATCCCCAGCACTCACTTTGCCTCTCAG-3' (33-mer, SEQ ID No.10) and
5'-CTGCGAATTCTACCGGTTTCTCTGCACCAGGTTC-3' (34-mer, SEQ ID No.11)

The DNA fragment was cleaved with BamHI and EcoRI, to recover a BamHI-EcoRI fragment of 481 base pairs, which was then inserted into plasmid pGEX-3X (manufactured by Pharmacia, Co.) preliminarily cleaved with BamHI and EcoRI, to recover plasmid pGST-DP-1 expressing a fused protein of a part of the human DP-1 (84-th to 241-th amino acid residues from the N terminus) with GST. The nucleotide sequence of each of the two plasmids in the regions of E2F-1 and DP-1 was determined, and it was verified that the sequences were not modified at all, compared with the sequences in the references

[0033] The two plasmids thus recovered, namely pGST-E2F-1 and pGST-DP-1, were introduced into an Escherichia coli XL1-blue (manufactured by Stratagene Co.) according to the method described in J. Mol. Biol., 166, 557 (1983). Then, one platinum loop of each of the resulting transfection strains pGST-E2F-1/XL1-blue and pGST-DP-1/XL1-blue was inoculated on a Terrific broth [1.2 % tryptic, 2.4 % yeast extract, 0.4 % glycerin, 0.1 M potassium hydrogen phosphate, pH 7.4] (40 ml) containing 50 µg/ml ampicillin in a 200-ml Erlenmeyer flask, for agitation culture at 30 °C overnight. Twenty milliliters of the culture solution were transferred into a 2-liter Erlenmeyer flask containing 400 ml of the same culture broth, for agitation culture at 30 °C. Immediately when the absorbance of the culture solution at 600 nm reached 0.8, isopropyl-β-D-thiogalactoside [IPTG manufactured by Wako Pure Chemical Industries Co., Ltd.] was added to the culture solution to 0.1 mM, for culturing at 30 °C for another 4 hours. From the culture solution were collected bacteria cells by centrifugation, which were then rinsed in ice-cold physiological saline [PBS (phosphate buffered saline) containing 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na₂HPO₄, and 1.5 mM KH₂PO₄] and were then suspended in 20 ml of PBS containing 0.1 mM phenylmethylsulfonyl fluoride [PMSF, manufactured by Sigma Co.]. The suspension was treated five times with ultrasonication for one minute, followed by addition of Triton X-100, Tween-20 and Sarcosyl to each final concentration of 1 %, for subsequent gradual agitation at 4 °C for 60 minutes. The treated solution was centrifuged to recover the supernatant, followed by addition of 400 µl of glutathione-Sepharose CL-4B (manufactured by Pharmacia Co.), prior to gradual agitation at 4 °C for 60 minutes. Through centrifugation, the precipitate was recovered, rinsed three times in PBS (5 ml) containing 0.1 mM PMSF, and eluted with 1.2 ml of 50 mM Tris-HCl buffer (pH 8.0) containing 10 mM glutathione (manufactured by Wako Pure Chemical Industries Co., Ltd.), to recover objective fused proteins GST-E2F-1 and GST-DP-1.

(1-2) Gel shift experiments by using GST-E2F-1 and GST-DP-1

[0034] The following two oligonucleotides, including the E2F binding sequence, which are complementary sequences to each other,

5'-ATTTAAGTTTTCGCGCCCTTTCTCAA-3' (25-mer, SEQ ID No.12) and
5'-TTGAGAAAGGGCGCGAACTTAAAT-3' (25-mer, SEQ ID No.13)

were added individually at a concentration of 10 µM into a solution comprising 10 mM MgCl₂, 5 mM DTT and 50 mM Tris-HCl(pH 7.5), for treatment at 75 °C for 10 minutes, and the resulting solutions were left to stand at ambient temperature while gradually lowering the temperature for annealing. The resulting double-stranded DNA solution (10 µl) was kept in a reaction solution (30 µl) [50 mM Tris-HCl buffer(pH 7.5) containing 10 mM MgCl₂, 5 mM dithiothreitol (DTT), 10 units of T4 polynucleotide kinase (manufactured by Takara), 0.2 mCi [γ -³²P]ATP (7,000 Ci/mmol ATP manufactured by Amersham Co.)] at 37 °C for 60 minutes, to label the 5' terminus. By adding 0.5 M EDTA (2 µl) to the reaction solution, the reaction was terminated, and thereafter, unreactive [γ -³²P]ATP was removed by using a Nick Column G-50 (manufactured by Pharmacia Co.) to recover E2F probe. Into 20 mM HEPES buffer(pH 7.4)(20 µl) containing 40 mM KCl, 1 mM MgCl₂, 0.1 mM EDTA, 0.1 % Nonidet P-40, and 1 mM DTT were added 0.1 pmol of ³²P-labeled E2F probe.

100 ng of GST-E2F-1, 100 ng of GST-DP-1, 2 μ g of calf thymus DNA and 0 to a 100 μ M test compound, for reaction at 30 °C for 30 minutes. After the reaction, the reaction solution was electrophoresed by using 0.5×TBE [2.5 mM Tris-borate buffer, pH 8.3, 0.1 mM EDTA] as an electrophoresis buffer in 4 % polyacrylamide gel. GST-E2F-1 and GST-DP-1 proteins were bound to the labeled E2F probe, so that the mobility thereof was reduced. Accordingly, the proteins were detected as upper bands. After electrophoresis, the gel was dried to assay the radioactivity in bands shifting upward, by using an image analyzer Type BAS2000 (manufactured by Fuji Film Co.). The radioactivity in each lane was assayed, to calculate the inhibition ratio, on the basis of the radioactivity of a sample with no test compound contained in the reaction system, according to the following equation.

$$\text{Inhibition ratio} = (A - B) / A$$

A: radioactivity in a band shifted in the absence of any test compound

B: radioactivity in a band shifted in the presence of a test compound.

Table 2

Compounds	Concentration (μ M)	Inhibition ratio (%)	IC ₅₀ (μ M)
1a-1	1	29.7	2
	10	90.5	
	100	96.5	
1a-3	10	18.3	23
	25	50.6	
	100	86.2	
1b-1	1	11.7	10
	10	52.9	
	100	87.6	
1b-3	25	17.9	100
	100	49.5	

IC₅₀: compound concentration at which the inhibition ratio is 50 %

Test Example 2

Assay of growth inhibiting activity on Saos-2 cell

[0035] 1×10^5 cells of a human osteosarcoma-derived cell line Saos-2 (ATCC HTB85) cultured in an RPMI 1640 culture medium containing 10 % fetal calf serum (manufactured by Nissui Co., referred to as medium A hereinbelow) in the presence of 5 % CO₂ at 37 °C were suspended in 50 μ l of K-PBS buffer [137 mM KCl, 2.7 mM NaCl, 8.1 mM Na₂HPO₄, 1.5 mM KH₂PO₄, and 4 mM MgCl₂], followed by addition of a test compound appropriately diluted with K-PBS to a final concentration of 100 μ M. The suspension was transferred on a 0.2-cm width cuvette (manufactured by BIO-RAD Laboratories) for loading an electric pulse (conditions: an electric voltage = 3 kV/cm, a pulse width = 100 μ seconds, a pulse interval = one second, a pulse number = two) by using a Shimadzu cell fusion system SSH-1 (manufactured by Shimadzu Corporation). After leaving the cuvette to stand for 10 minutes, the cells were recovered and suspended in 3 ml of the medium A, for inoculation on a cell culture dish of a 60-mm diameter (manufactured by Iwaki Glass Co.). In the presence of 5 % CO₂, the cells were cultured at 37 °C for 40 hours and were then peeled off by means of PBS containing 0.05 % trypsin and 0.02 % EDTA and dyed with 0.05 % trypan blue, to count the number of viable cells by means of a modified Neubauer hemocytometry. Based on the cell number with no test compound under load of an electric pulse, the inhibition ratio was calculated by the following equation.

$$\text{Inhibition ratio} = (A - B) / A$$

A: viable cell number in the absence of any test compound

B: viable cell number in the presence of a test compound

[0036] The results are shown in Table 3

Table 3

Compounds	Inhibition ratio (%)
la-1	25
lb-1	73

Test Example 3

Assay of activity suppressing E2F responsive transcription (1)

[0037] The promoter sequence of human cdc2 gene [EMBO J. 11, 1797 (1992)], which has been reported to have an endogenous E2F responsive sequence and to effect an E2F dependent transcription, was bound to the upstream of the firefly luciferase gene, which was designated as reporter gene. The promoter region of the human cdc2 gene was cloned as follows. By using the following two oligonucleotides primers,

5'-CTATACACTCCTAACCCTAAGTATTAGAAG-3' (30-mer, SEQ ID No 14) and
5'-AGCTACAACAACGCGTCGCTCTCCGCTC-3' (28-mer, SEQ ID No 15).

466-bp DNA in the human cdc2 promoter region was amplified from human genome DNA [Clontech Laboratories Inc.] by PCR as described above. The DNA fragment was cloned into a PCR product cloning vector pCRII [manufactured by Invitrogen Co.]. From the plasmid was cleaved a DNA fragment with restriction enzymes HindIII and XhoI, and the fragment was inserted into a HindIII-XhoI site of luciferase reporter vector pluc2 [Eur. J. Haematol. 52, 73 (1994)], to generate a reporter plasmid pcdc21uc2.

[0038] Two micrograms (2 μ g) of the plasmid pcdc21uc2 thus prepared were introduced, together with a test compound (100 μ M), into 1×10^6 cells of Saos-2 by electroporation, in the same manner as in the Test Example 2. As in the Test Example 2, the resulting cells were inoculated into a cell culture dish of a 60-mm diameter for culturing in the presence of 5 % CO₂ at 37 °C for 40 hours, and thereafter, the cells were peeled off and recovered by centrifugation. The cells were suspended in 0.5 ml of a cell lysis buffer [1 % Triton X-100, 100 mM KH₂PO₄(pH 7.8), 1 mM dithiothreitol] and centrifuged, to recover the supernatant, of which 200 μ l was then used to assay the luciferase activity and of which 10 μ l was used to assay the protein concentration. The luciferase activity was assayed as follows. 300 μ l of a substrate solution [25 mM glycylglycine buffer(pH 7.8), 15 mM MgSO₄, 5 mM ATP, and 0.33 mM luciferin] was automatically injected into a luminometer LB953 (manufactured by Berthold Co.), to assay the luminescence for 10 seconds, which was defined as luciferase activity. The protein concentration was assayed with a protein assay kit (manufactured by BIO-RAD Laboratories), which was used to correct the luciferase activity. Based on the luciferase activity (after correction with protein concentration) of a sample with no test compound contained in the reaction system, the inhibition ratio was calculated by the following equation

$$\text{Inhibition ratio} = (A - B) / A$$

A. luciferase activity in the absence of any test compound (after correction with protein concentration)

B. luciferase activity in the presence of a test compound (after correction with protein concentration)

[0039] The results are shown in Table 4

Table 4

Compounds	Inhibition ratio (%)
la-1	25
b-1	83

Test Example 4

Assay of activity suppressing E2F responsive transcription (2) (4-1) Construction of reporter cell strain

[0040] Into the XhoI- and HindIII sites of luciferase reporter vector pluc2 with neomycin (G418) resistant gene [Eur. J. Haematol., 52, 73 (1994)] were inserted an SphI-HindIII fragment composed of the 200 base pairs in the core promoter region of the SV40 initial gene [128-0/5243-5171, base number according to Tooze, J. Molecular Biology of Tumor Viruses, 2nd Ed., Part 2 Revised, DNA Tumor Viruses, Cold Spring Harbor Laboratory Press, 1982], and a fragment produced by annealing the following two synthetic oligonucleotides:

5'-TCGAGCCCCGGGGGTACCGCATG-3' (22-mer; SEQ ID No.16) and
5'-CGGTACCCCCGGGC-3' (14-mer; SEQ ID No.17)

which fragment had XhoI and SphI sites at both the termini and had an SmaI and Asp718 (KpnI) sites, to create luciferase reporter vector pSE01uc2 for inserting a transcription regulatory region therein

[0041] By then annealing together the following two oligonucleotides having an E2F responsive sequence inside and being complimentary to each other

5' - TCGAGCTTGGCGGGGAACTTGGCGGGGAACTTGGCG
GGAACTTGGCGGGGAAAGTCGACG - 3' (60-mer; SEQ ID
No.18) and

5' - GTACCGTCGACTTTCCCGCCCAAGTTTCCCGCCCAAGT
TTCCCGCCCAAGTTTCCCGCCCAAGC - 3' (60-mer; SEQ ID
No.19),

and then inserting the annealed product into the XhoI and Asp718 sites of the constructed luciferase vector pSE01uc2, reporter plasmid pE2FII-1luc2 was constructed.

[0042] By the following method, the plasmid was introduced into a human osteosarcoma-derived cell strain Saos-2 (ATCC HTB85), and the resulting cell was defined as E2F responsive reporter cell. 2×10^7 cells of the Saos-2 cultured in the presence of 5 % CO₂ in the medium A at 37 °C were suspended in K-PBS buffer (50 µl) [137 mM KCl, 2.7 mM NaCl, 8.1 mM Na₂HPO₄, 1.5 mM KH₂PO₄, 4 mM MgCl₂], followed by addition of 1 µg/µl plasmid pE2FII-1 luc2 (4 µg) prepared above. The suspension was transferred on a 0.2-cm width cuvette (manufactured by BIO-RAD Laboratories) for loading an electric pulse (conditions: an electric voltage = 3 kV/cm, a pulse width = 100 µ seconds, a pulse interval = one second, a pulse number = two) by using a Shimadzu cell fusion system SSH-1 [manufactured by Shimadzu Corporation] to introduce the gene by electroporation. After leaving the cuvette to stand for 10 minutes, the cells were recovered and suspended in 10 ml of the medium A, for inoculation on a cell culture dish of a 100-mm diameter (manufactured by Iwaki Glass Co.)

[0043] Twenty-four hours after the introduction of the gene, the medium was exchanged to medium A containing 0.2 mg/ml Geneticin[®] (G418 sulfate; manufactured by GIBCO BRL), to select clones with the introduced plasmid stably incorporated in the chromosome. On the fourteenth day after the introduction of the gene, clones having formed a single colony on the dish were separated by using a cloning cylinder. From the resulting clones were selected a reporter cell strain with response to E2F to induce luciferase activity, namely E2F-1/Saos-2-1, was recovered by using the response to the E2F-1 and RB introduction as a marker.

(4-2) Assay of transcription suppressing activity

[0044] A test compound was introduced into the cell strain E2F-1/Saos-2-1 obtained above by using Lipofect AMINE[™] (manufactured by GIBCO-BRL) described below, to assay the E2F dependent transcription suppressing activity as luciferase activity. 4×10^7 cells of E2F-1/Saos-2-1 were inoculated in the medium A in a 35-mm cell culture dish for culturing in the presence of 5 % CO₂ at 37 °C for 24 hours. In 0.2ml of Opti-MEM[™] medium (manufactured by GIBCO-BRL) were

dissolved 3 μ l of Lipofect AMINE™ and 1 or 10 nmol of a test compound, and the resulting solution was left to stand at ambient temperature for 15 minutes, followed by further addition of Opti-MEM^{RI} medium (0.8 ml). From the cells was removed the solution, and then, the cells were rinsed in the Opti-MEM^{RI} medium, to which was then added one milliliter of the solution, for culturing in the presence of 5 % CO₂ at 37 °C for 6 hours (the final concentration of the test compound was 1 or 10 μ M). Six hours later, one milliliter of the medium A was added to the culture, for another 48-hour culturing, and then, the cells were peeled off and recovered by centrifugation. The cells were suspended in a cell lysis buffer (0.5 ml) [1 % Triton X-100, 100 mM KH₂PO₄(pH 7.8), 1 mM dithiothreitol] and were thereafter centrifuged to recover the supernatant. 200 μ l of the supernatant was used to assay the luciferase activity, while 10 μ l thereof was used to assay the protein concentration. The luciferase activity was assayed as follows: 300 μ l of a substrate solution [25 mM glycylglycine buffer(pH 7.8), 15 mM MgSO₄, 5 mM ATP, and 0.33 mM luciferin] was automatically injected into a luminometer LB953 (manufactured by Beltold Co.), to assay the luminescence for 10 seconds, which was defined as luciferase activity. The protein concentration was assayed with a protein assay kit (manufactured by BIO-RAD Laboratories), which was used to correct the luciferase activity. Based on the luciferase activity (after correction with the protein concentration) of a sample with no test compound contained in the reaction system, the inhibition ratio was calculated by the following equation

$$\text{Inhibition ratio} = (A - B) / A$$

A: luciferase activity in the absence of any test compound (after correction with protein concentration)

B: luciferase activity in the presence of a test compound (after correction with protein concentration)

[0045] The results are shown in Table 5

Table 5

Compound	Concentration (μ M)	Inhibition ratio (%)
Ic-1	1	17
	10	28

Test Example 5

Growth inhibition of human epidermoid carcinoma cell A431 and human colon cancer cell SW480

[0046] Human epidermoid carcinoma cell A431 (ATCC CRL-1555) or human colon cancer cell SW480 (ATCC CCL-228), preliminarily adjusted to 1×10^4 cells/ml in a DME culture medium (Nissui Co.) containing 10% fetal calf serum, was divided in a 0.1-ml portion into each well of a 96-well microtiter plate (Nunk Co., #167008). The cells were cultured in a CO₂ gas incubator at 37 °C for 24 hours, followed by addition of 0.05 ml of the test compound preliminarily diluted appropriately with the culture medium into each well, for subsequent culturing in a CO₂ gas incubator at 37 °C for 72 hours. After removing the culture supernatant, each well was rinsed in 0.15 ml of PBS buffer, followed by fresh addition of 0.05 ml of the culture medium into each well. The cell number in each well was counted by a cell proliferation kit II manufactured by Boehringer Mannheim Co. After adding 0.025 ml of colorimetric reagent to each well and keeping the plate in a CO₂ gas incubator at 37 °C for 3 hours, the absorbance at 490 nm and 655 nm was determined with a microplate reader Model 550 (manufactured by BIO-RAD Laboratories), to calculate then the value (difference in absorbance) of the absorbance of each well at 490 nm (A₄₉₀) minus the absorbance thereof at 655 nm (A₆₅₅). Comparing the difference in absorbance between the non-treated cells and the cells treated with the test compound at the predetermined concentration, the cell growth inhibiting activity of the test compound at each concentration was calculated by the following equation

$$\text{Inhibition ratio} = (A - B) / A$$

A: difference in absorbance in the absence of any test compound (A₄₉₀ - A₆₅₅)

B: difference in absorbance in the presence of a test compound (A₄₉₀ - A₆₅₅)

[0047] The results are shown in Table 6

Table 6

Compound	Concentration (μ M)	Inhibition ratio (%)	
		A431 cells	SW480 cells
Ia-3	33	21	41
Ib-3	11	22	14
Ib-3	33	42	44

[0048] The Compound (I) and the pharmaceutically acceptable salt thereof obtained in accordance with the present invention are useful as an anti-tumor agent or anti-arteriosclerosis agent and may satisfactorily be used as they are or at various dosing formulations. For example, the Compound (I) or the pharmaceutically acceptable salt thereof may be dissolved in physiological saline or an aqueous solution of glucose, lactose, mannitol or the like, and the resulting solution can be used as an appropriate pharmaceutical injection. For example, additionally, the Compound (I) or the pharmaceutically acceptable salt thereof is lyophilized, to which is added sodium chloride, to prepare a powdery injection. If needed, the pharmaceutical composition may contain additives well known in the pharmaceutical field, e.g. pharmaceutically acceptable salts.

[0049] The Compound (I) or the pharmaceutically acceptable salt thereof may be mixed and formulated with appropriate excipients, disintegrators, binders and lubricants, to prepare tablets, granules, powders and syrups in the form of oral agents. Still additionally, the Compound (I) or the pharmaceutically acceptable salt thereof may be mixed and formulated with routine carriers, to prepare suppositories, which may be administered into rectum.

[0050] The dose may vary, depending on the dosage route, the type of the Compound (I) or the pharmaceutically acceptable salt thereof, the age and conditions of a patient and the like, while the dosage may also be variable, depending on the conditions and the dose. For example, the Compound (I) or the pharmaceutically acceptable salt thereof may be administered at 0.0001 to 100 mg/kg per day, preferably 0.001 to 10 mg/kg per day and more preferably 0.01 to 1 mg/kg per day.

Best Mode for Carrying out the Invention

[0051] The present invention is now described in the following examples.

[0052] In the following examples, the physico-chemical properties of compounds were determined by the following methods. For mass analysis according to the FAB method, JEOL JMS-SX102A was used. Amino acid analysis was carried out according to the method of Bidlingmeyer et al. [J. Chromatogr., 336, 93 (1984)]. Hydrolysis was effected in the vapor of hydrochloric acid at 110 °C for 22 hours, and the amino acid composition of the hydrolysis product was analyzed by using an amino acid analyzer Pico Tag (manufactured by Waters Associates).

Example 1

Synthesis of Compound Ia-1

[0053]

(CH₃-CC-Leu-Asn-Trp-Ala-Ala-Glu-Val-Leu-Lys-Val-Gln-Lys-Arg-Arg-Ile-Tyr-Asp-Ile-Thr-Asn-Val-Leu-Glu-Gly-Ile-Gln-Leu-Ile-Ala-NH₂, SEQ ID No. 1)

[0054] A carrier resin (30 mg) bonded with Fmoc-NH (14.1 μ mol) (Pink Amide MBHA resin) was placed in the reactor of an automatic synthesizer, so as to practice the following procedures according to the synthesis program instructed by Shimadzu Corporation.

- The carrier resin was rinsed in DMF for 3 minutes, and then the solution was discarded.
- After adding a 30% solution (900 μ l) of piperidine in DMF to the resin, the resulting mixture was agitated for 4 minutes, and then, the solution was discarded. The procedure was repeated once more.
- The carrier resin was rinsed in DMF for one minute, and the solution was discarded. The procedure was repeated five times. In such manner, the Fmoc-removed carrier resin bonded with NH₂ was recovered.
- Fmoc-Ala-OH (70.5 μ mol), PyBOP (70.5 μ mol), HOBt \cdot monohydrate (70.5 μ mol) and NMM (105.75 μ mol)

were agitated together in DMF (246.8 μ l) for 3 minutes, and the resulting solution was added to the carrier resin. Then, the resulting mixture was agitated for 30 minutes, from which the solution was discarded.

(e) The carrier resin was rinsed in DMF for one minute, and the procedure was repeated five times. In such manner, Fmoc-Ala-NH was synthesized on the carrier resin.

[0055] After the procedures (a) to (c) for rinsing and deprotection, condensation reaction was carried out by using Fmoc-Ile-OH at the process (d), and through the rinse process (e), Fmoc-Ile-Ala was synthesized on the carrier resin. By subsequently using the following compounds at the process (d) and repeating the processes (a) to (e), a carrier resin bonded with protective peptide was recovered.

Fmoc-Leu-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ile-OH, Fmoc-Gly-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Leu-OH, Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Asp(Ot-Bu)-OH, Fmoc-Tyr(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Val-OH, Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Val-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Trp-OH, Fmoc-Asn(Trt)-OH, and Fmoc-Leu-OH.

[0056] After further rinsing and deprotection processes (a) to (c), 50 % acetic anhydride-containing DMF (1 ml) was added to the carrier resin, and the resulting mixture was agitated for 30 minutes. Then, the solution was discarded. The carrier resin was rinsed in DMF for one minute, the procedure was repeated five times, followed by sequential rinsing in methanol and butyl ether and drying under reduced pressure for 12 hours, and a carrier resin bonded with the peptide with a side-chain protective group was recovered. To the resin was added a mixture solution (800 μ l) composed of 82.5 % of TFA, 5 % of thioanisole, 5 % of water, 3 % of ethyl methyl sulfide, 2.5 % of 1,2-ethanedithiol and 2 % of thiophenol and containing 2-methylindole at a ratio of 5 mg/ml, and the resulting mixture was left to stand at ambient temperature for 6 hours, to remove the side-chain protective groups and cleave the peptide from the carrier resin. After filtering off the carrier resin, about 10 ml of ether was added to the resulting solution. Through centrifugation and decantation, the generated precipitate was recovered as 39.1 mg of a crude peptide. The crude product was dissolved in 2M acetic acid, followed by HPLC purification on a reverse-phase column (CAPCELL PAK C18 of 30 mm I.D. \times 250 mm, manufactured by Shiseido, Co., Ltd.). The peptide was eluted on a linear gradient of 0.1 % TFA - 90 % acetonitrile containing 0.1 % TFA, as prepared by adding an aqueous 90 % acetonitrile solution containing 0.1 % TFA into an aqueous 0.1 % TFA solution. The peptide was detected at 220 nm. Thus, a fraction containing the entitled compound was recovered. By lyophilizing the fraction, 7.5mg of Compound Ia-1 was recovered.

Mass spectrum [FABMS], 3406 (M + H)

Amino acid analysis.

Asx 2.7 (3), Glx 4.4 (4), Gly 1.3 (1), Arg 1.8 (2), Thr 0.8 (1), Ala 3.5 (3), Tyr 0.9 (1), Val 2.6 (3), Ile 3.7 (4), Leu 4.1 (4), Lys 2.1 (2). Trp not determined.

Example 2

Synthesis of Compound Ia-2

[0057]

(CH₃-Co-Val-Leu-Lys-Val-Gln-Lys-Arg-Arg-Ile-Tyr-Asp-Ile-Thr-Asn-Val-NH₂, SEQ ID No 2)

[0058] In the same manner as in Example 1, a carrier resin (30 mg) bonded with 14.7 μ mol of Fmoc-NH as a starting material was condensed sequentially with

Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Asp(Ot-Bu)-OH, Fmoc-Tyr(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Val-OH, Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, and Fmoc-Val-OH.

[0059] As in Example 1, through the reaction with acetic anhydride followed by rinsing and drying, a carrier resin bonded with a side-chain protected peptide was recovered, into which was added a mixture solution (800 μ l) of 82.5 % of TFA, 5 % of thioanisole, 5 % of water, 3 % of ethyl methyl sulfide, 2.5 % of 1,2-ethanedithiol and 2 % of thiophenol. The resulting mixture was left to stand at ambient temperature for 8 hours, to remove the side-chain protective groups and cleave the peptide from the carrier resin. As in Example 1, 40.7 mg of a crude peptide was recovered, followed by HPLC purification on a reverse-phase column, to recover 20.1 mg of Compound Ia-2.

Mass spectrum [FABMS], 1885 (M + H)

Amino acid analysis.

Asx 1 9 (2), Glx 1 1 (1), Arg 2 1 (2), Thr 1 0 (1), Tyr 1 0 (1), Val 3 0 (3), Ile 2 0 (2), Leu 1 0 (1), Lys 1 9 (2)

Example 3

Synthesis of Compound Ib-1

[0060]

(CH₃-CC-Asn-Glu-Ser-Ala-Tyr-Asp-Gln-Lys-Asn-Ile-Arg-Arg-Arg-Val-Tyr-Asp-Ala-Leu-Asn-Val-Leu-Met-Ala-Met-Asn-Ile-Ile-Ser-NH₂, SEQ ID No.3)

[0061] In the same manner as in Example 1, a carrier resin (30 mg) bonded with 14.1 μmol of Fmoc-NH as a starting material was condensed sequentially with

Fmoc-Ser(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Ile-OH, Fmoc-Asn(Trt)-OH, Fmoc-Met-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-Ala-OH, Fmoc-Asp(Ot-Bu)-OH, Fmoc-Tyr(t-Bu)-OH, Fmoc-Val-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Ile-OH, Fmoc-Asn(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Asp(Ot-Bu)-OH, Fmoc-Tyr(t-Bu)-OH, Fmoc-Ala-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Glu(Ot-Bu)-OH, and Fmoc-Asn(Trt)-OH

[0062] As in Example 1, through the reaction with acetic anhydride followed by rinsing and drying, a carrier resin bonded with a side-chain protected peptide was recovered, into which was added a mixture solution (800 μl) of 82.5 % of TFA, 5 % of thioanisole, 5 % of water, 3 % of ethyl methyl sulfide, 2.5 % of 1,2-ethanedithiol and 2 % of thiophenol. The resulting mixture was left to stand at ambient temperature for 8 hours, to remove the side-chain protective groups and cleave the peptide from the carrier resin. As in Example 1, 34.7 mg of a crude peptide was recovered, followed by HPLC purification on a reverse-phase column, to recover 6.3 mg of Compound Ib-1.

Mass spectrum [FABMS], 3337 (M + H)

Amino acid analysis:

Asx 6 4 (6), Glx 2 4 (2), Ser 2 4 (2), Arg 2 5 (3), Ala 3 6 (3), Tyr 2 2 (2), Val 1 5 (2), Met 2 1 (2), Ile 2 0 (3), Leu 1 7 (2), Lys 1 2 (1)

Example 4

Synthesis of Compound Ib-2

[0063]

(CH₃-Co-Ile-Arg-Arg-Arg-Val-Tyr-Asp-Ala-Leu-Asn-Val-Leu-Met-Ala-Met-NH₂, SEQ ID No.4)

[0064] In the same manner as in Example 1, a carrier resin (30 mg) bonded with 14.7 μmol of Fmoc-NH as a starting material was condensed sequentially with

Fmoc-Met-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-Ala-OH, Fmoc-Asp(Ot-Bu)-OH, Fmoc-Tyr(t-Bu)-OH, Fmoc-Val-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Arg(Pmc)-OH, and Fmoc-Ile-OH

[0065] As in Example 1, through the reaction with acetic anhydride followed by rinsing and drying, a carrier resin bonded with a side-chain protected peptide was recovered, into which was added a mixture solution (800 μl) of 82.5 % of TFA, 5 % of thioanisole, 5 % of water, 3 % of ethyl methyl sulfide, 2.5 % of 1,2-ethanedithiol and 2 % of thiophenol. The resulting mixture was left to stand at ambient temperature for 8 hours, to remove the side-chain protective groups and cleave the peptide from the carrier resin. As in Example 1, 29.0 mg of a crude peptide was recovered, followed by HPLC purification on a reverse-phase column, to recover 5.9mg of Compound Ib-2

Mass spectrum [FABMS], 1861 (M + H)

Amino acid analysis.

Asx 2 0 (2), Arg 3 0 (3), Ala 2 1 (2), Tyr 1 0 (1), Val 1 8 (2), Met 2 1 (2), Ile 1 0 (1), Leu 2 0 (2)

Example 5

Synthesis of Compound Ic-1

[0066]

(CH₃-CO-Ala-Arg-Gly-Arg-Gly-Arg-His-Pro-Gly-Lys-Gly-Val-Lys-Ser-Pro-Gly-Glu-Arg-Ser-Arg-Tyr-Glu-Thr-Ser-Leu-Asn-Leu-Thr-Thr-Lys-Arg-Phe-Leu-Glu-Leu-NH₂, SEQ ID No.5)

[0067] In the same manner as in Example 1, a carrier resin (20 mg) bonded with 9.8 μmol of Fmoc-NH as a starting material was condensed sequentially with

Fmoc-Leu-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Thr(t-Bu)-OH, Fmoc-Thr(t-Bu)-OH, Fmoc-Leu-OH, Fmoc-Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Thr(t-Bu)-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Tyr(t-Bu)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Gly-OH, Fmoc-Pro-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Val-OH, Fmoc-Gly-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Pro-OH, Fmoc-His(Trt)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pmc)-OH, and Fmoc-Ala-OH

[0068] As in Example 1, through the reaction with acetic anhydride followed by rinsing and drying, a carrier resin bonded with a side-chain protected peptide was recovered, into which was added a mixture solution (800 μl) of 82.5 % of TFA, 5 % of thioanisole, 5 % of water, 3 % of ethyl methyl sulfide, 2.5 % of 1,2-ethanedithiol and 2 % of thiophenol. The resulting mixture was left to stand at ambient temperature for 8 hours, to remove the side-chain protective groups and cleave the peptide from the carrier resin. As in Example 1, 38.7 mg of a crude peptide was recovered, followed by HPLC purification on a reverse-phase column, to recover 5.6 mg of Compound Ic-1.

Mass spectrum [FABMS], 3993 (M + H)

Amino acid analysis:

Asx 1.1 (1), Glx 3.0 (3), Ser 2.6 (3), Gly 5.6 (5), His 1.1 (1), Arg 5.0 (6), Thr 2.9 (3), Ala 1.0 (1), Pro 2.2 (2), Tyr 0.8 (1), Val 0.9 (1), Leu 4.4 (4), Phe 1.0 (1), Lys 3.2 (3)

Example 6

Synthesis of Compound Ia-3

[0069]

[CH₃-(CH₂)₁₀-Co-Leu-Asn-Trp-Ala-Ala-Glu-Val-Leu-Lys-Val-Gln-Lys-Arg-Arg-Ile-Tyr-Asp-Ile-Thr-Asn-Val-Leu-Glu-Gly-Ile-Gln-Leu-Ile-Ala-NH₂, SEQ ID No.20]

[0070] A carrier resin (100 mg) bonded with 20 μmol of Fmoc-NH (NovaSyn TGR Resin, manufactured by Nova Biochem, Co.) as a starting material was subjected to the following procedures by using a peptide synthesizer manufactured by ACT Inc.

(a) The carrier resin was rinsed in DMF (1 ml) under agitation for 3 minutes, and then, the solution was discarded. The procedure was repeated twice.

(b) After adding a 25% solution (1 ml) of piperidine in DMF to the resin, the resulting mixture was agitated for 2 minutes, and then, the solution was discarded. After adding again the 25% solution (1 ml) of piperidine in DMF to the resin, the resulting mixture was further agitated for 10 minutes, and then, the solution was discarded.

(c) The carrier resin was rinsed in DMF (1 ml) under agitation for one minute, and the solution was discarded. The procedure was repeated seven times.

In such manner, a carrier resin from which any Fmoc group was removed was recovered.

(d) DMF (250 μl), an NMP solution (500 μl) containing Fmoc-Ala-OH and HOBt monohydrate, individually at a concentration of 0.5 M, and an NMP solution containing DIC at a concentration of 0.5 M, were added to the resin, for 45-min agitation, and then, the solution was discarded.

(e) The carrier resin was rinsed in DMF (1 ml) under agitation for one minute, and then, the resin was again rinsed

in DMF (1 ml)

(f) DMF (250 μ l), an NMP solution (500 μ l) containing Fmoc-Ala-OH and HOBt monohydrate, individually at a concentration of 0.5 M, a DMF solution (500 μ l) containing HBTU at a concentration of 0.5 M, and an NMP solution (250 μ l) containing DIEA at a concentration of 2 M were added to the resin, for 30-min agitation, and then, the solution was discarded

(g) The procedure (e) was repeated twice

[0071] In such manner, Fmoc-Ala-NH was synthesized on the carrier resin

[0072] After the procedures (a) to (c) for rinsing and deprotection, condensation reaction was carried out by using a solution containing Fmoc-Ile-OH instead of Fmoc-Ala-OH at the processes (d) and (f), and through the rinse processes (e) and (g), Fmoc-Ile-Ala-NH was synthesized on the carrier resin. By subsequently using the following compounds at the processes (d) and (f) and repeating the processes (a) to (g), a carrier resin bonded with a protective peptide was recovered.

Fmoc-Leu-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ile-OH, Fmoc-Gly-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Leu-OH, Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Asp(Ot-Bu)-OH, Fmoc-Tyr(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Val-OH, Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Val-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Trp(Boc)-OH, Fmoc-Asn(Trt)-OH, and Fmoc-Leu-OH

[0073] After further rinsing and deprotection processes (a) to (c), a DMF solution (500 μ l) containing 20 mg lauric acid, a DMF solution (500 μ l) containing HBTU at a concentration of 0.5 M, and an NMP solution (250 μ l) containing DIEA at a concentration of 2M were added to the resin, and the resulting mixture was agitated for 12 hours. Then, the solution was discarded. The carrier resin was rinsed and dried as in Example 1, to recover a carrier resin bonded with a side-chain protected peptide. To the above carrier resin was added a mixture solution (1200 μ l) composed of 82.5 % of TFA, 5 % of thioanisole, 5 % of water, 3 % of ethyl methyl sulfide, 2.5 % of 1,2-ethanedithiol, 2 % of thiophenol and 2-methylindole (5 mg/ml), and the resulting mixture was left to stand at ambient temperature for 6 hours, to remove the side-chain protective groups and cleave the peptide from the carrier resin. In the same manner as in Example 1, 53.0 mg of a crude peptide was recovered, followed by HPLC purification on a reverse-phase column, to recover 5.3 mg of Compound Ia-3.

Mass spectrum [FAB/MS], 3546 (M + H)

Amino acid analysis,

Asx 2.8 (3), Glx 4.1 (4), Gly 1.3 (1), Arg 2.0 (2), Thr 1.0 (1), Ala 3.2 (3), Tyr 1.0 (1), Val 2.7 (3), Ile 3.3 (4), Leu 4.0 (4), Lys 2.0 (2). Trp not determined

Example 7

Synthesis of Compound Ib-3

[0074]

$[\text{CH}_2(\text{CH}_2)_4\text{---CO-Asn-Glu-Ser-Ala-Tyr-Asp-Gln-Lys-Asn-Ile-Arg-Arg-Arg-Val-Tyr-Asp-Ala-Leu-Asn-Val-Leu-Met-Ala-Met-Asn-Ile-Ile-Ser-NH}_2]$, SEQ ID No.21]

[0075] In the same manner as in Example 6, a carrier resin (100 mg) bonded with 20 μ mol of Fmoc-NH as a starting material was condensed sequentially with

Fmoc-Ser(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Ile-OH, Fmoc-Asn(Trt)-OH, Fmoc-Met-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-Ala-OH, Fmoc-Asp(Ot-Bu)-OH, Fmoc-Tyr(t-Bu)-OH, Fmoc-Val-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Ile-OH, Fmoc-Asn(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Asp(Ot-Bu)-OH, Fmoc-Tyr(t-Bu)-OH, Fmoc-Ala-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Glu(Ot-Bu)-OH, and Fmoc-Asn(Trt)-OH

[0076] As in Example 6, through the reaction with lauric acid, followed by rinsing and drying, a carrier resin bonded with a side-chain protected peptide was recovered, into which was added a mixture solution (1200 μ l) of 82.5 % of TFA, 5 % of thioanisole, 5 % of water, 3 % of ethyl methyl sulfide, 2.5 % of 1,2-ethanedithiol and 2 % of thiophenol. The resulting mixture was left to stand at ambient temperature for 8 hours, to remove the side-chain protective groups and cleave

the peptide from the carrier resin. As in Example 1, 47.9 mg of a crude peptide was recovered, followed by HPLC purification on a reverse-phase column, to recover 2.2 mg of Compound Ib-3.

Mass spectrum [FABMS], 3477 (M + H)

Amino acid analysis:

Asx 5.9 (6), Glx 2.0 (2), Ser 2.0 (2), Arg 2.9 (3), Ala 3.4 (3), Tyr 2.1 (2), Val 1.9 (2), Met 2.3 (2), Ile 2.2 (3), Leu 2.2 (2), Lys 1.1 (1)

Industrial Applicability

[0077] In accordance with the present invention, a novel compound inhibiting the E2F activity and having excellent anti-tumor activity or anti-arteriosclerosis activity can be provided. The compound is useful as a therapeutic agent of diseases such as tumor and arteriosclerosis, for which abnormal cell growth is responsible.

SEQUENCE LISTING

Sequence ID No.1

Length; 29

Type; amino acid

Strandedness; single

Topology; linear

Molecule type; peptide

Sequence feature

Name/Key; Modified-site

Location; 1

Identification method of feature; E

Other information; Xaa at position 1 representing N-acetyl-L-leucine

Name/Key; Modified-site

Location; 29

Identification method of feature; E

Other information; Xaa at position 29 representing L-alaninamide

Sequence Description

Xaa Asn Trp Ala Ala Glu Val Leu Lys Val Gln Lys Arg Arg Ile Tyr

1

5

10

15

Asp Ile Thr Asn Val Leu Glu Gly Ile Gln Leu Ile Xaa

20

25

Sequence ID No.2

Length; 15

Type; amino acid

Strandedness; single

Topology; linear

Molecule type; peptide

Sequence feature

Name/Key; Modified-site

Location; 1

Identification method of feature; E

Other information; Xaa at position 1 representing N-acetyl-L-valine

Name/Key; Modified-site

Location; 15

Identification method of feature; E

Other information; Xaa at position 15 representing L-valinamide

Sequence Description

Xaa Leu Lys Val Gln Lys Arg Arg Ile Tyr Asp Ile Thr Asn Xaa

1

5

10

15

Sequence ID No.3

Length; 28

Type; amino acid

Strandedness; single

Topology; linear

Molecule type; peptide

Sequence feature

Name/Key; Modified-site

Location; 1

Identification method of feature; E

Other information; Xaa at position 1 representing N-acetyl-
L-asparagine

Name/Key; Modified-site

Location; 28

Identification method of feature; E

Other information; Xaa at position 28 representing L-serinamide

Sequence Description

Xaa Glu Ser Ala Tyr Asp Gln Lys Asn Ile Arg Arg Arg Val Tyr Asp

1

5

10

15

Ala Leu Asn Val Leu Met Ala Met Asn Ile Ile Xaa

20

25

Sequence ID No.4

Length; 15

Type; amino acid

Strandedness; single

Topology; linear

Molecule type; peptide

Sequence feature

Name/Key; Modified-site

Location; 1

Identification method of feature; E

Other information; Xaa at position 1 representing N-acetyl-
L-isoleucine

Name/Key; Modified-site

Location; 15

Identification method of feature; E

Other information; Xaa at position 15 representing L-methioninamide

Sequence Description

Xaa Arg Arg Arg Val Tyr Asp Ala Leu Asn Val Leu Met Ala Xaa

1 5 10 15

Sequence ID No.5

Length; 35

Type; amino acid

Strandedness; single

Topology; linear

Molecule type; peptide

Sequence feature

Name/Key; Modified-site

Location; 1

Identification method of feature; E

Other information; Xaa at position 1 representing N-acetyl-L-alanine

Name/Key; Modified-site

Location; 35

Identification method of feature; E

Other information; Xaa at position 35 representing L-leucinamide

Sequence Description

Xaa Arg Gly Arg Gly Arg His Pro Gly Lys Gly Val Lys Ser Pro Gly

1 5 10 15

Glu Arg Ser Arg Tyr Glu Thr Ser Leu Asn Leu Thr Thr Lys Arg Phe

20 25 30

Leu Glu Xaa

35

Sequence ID No.6

Length; 38

Type; nucleic acid

Strandedness; single

Topology; linear

Molecule type; other nucleic acids synthetic DNA

Sequence Description

AGAGAGAAGC TTAAAGCGTC ATGCCCTTGG CCGGGGCC 38

Sequence ID No.7

Length; 26

Type; nucleic acid

Strandedness; single

Topology; linear

Molecule type; other nucleic acids synthetic DNA

Sequence Description

TTCTGCACCT TCAGCACCTC GGCAGC 26

Sequence ID No.8

Length; 26

Type; nucleic acid

Strandedness; single

Topology; linear

Molecule type; other nucleic acids synthetic DNA

Sequence Description

ACCAAGCGCT TCCTGGAGCT GCTGAG

26

Sequence ID No.9

Length; 26

Type; nucleic acid

Strandedness; single

Topology; linear

Molecule type; other nucleic acids synthetic DNA

Sequence Description

GGAAACCCTG GTACCTCCAA GCCCTG

26

Sequence ID No.10

Length; 33

Type; nucleic acid

Strandedness; single

Topology; linear

Molecule type; other nucleic acids synthetic DNA

Sequence Description

CCACGGATCC CCAGCACTCA CTTTGCCTCT CAG

33

Sequence ID No.11

Length; 34

Type; nucleic acid

Strandedness; single

Topology; linear

Molecule type; other nucleic acids synthetic DNA

Sequence Description

CTGCGAATTC TACCGGTTTC TCTGCACCAG GTTC

34

Sequence ID No.12

Length; 25

Type; nucleic acid

Strandedness; single

Topology; linear

Molecule type; other nucleic acids synthetic DNA

Sequence Description

ATTTAAGTTT CGCGCCCTTT CTCAA

25

Sequence ID No.13

Length; 25

Type; nucleic acid

Strandedness; single

Topology; linear

Molecule type; other nucleic acids synthetic DNA

Sequence Description

TTGAGAAAGG GCGCGAAACT TAAAT

25

Sequence ID No.14

Length; 30

Type; nucleic acid

Strandedness; single

Topology; linear

Molecule type; other nucleic acids synthetic DNA

Sequence Description

CTATACACTC CTAACCCTAA GTATTAGAAG

30

Sequence ID No.15

Length; 28

Type; nucleic acid

Strandedness; single

Topology; linear

Molecule type; other nucleic acids synthetic DNA

Sequence Description

AGCTACAACA ACGCGTCGCT CTCCGCTC

28

Sequence ID No.16

Length; 22

Type; nucleic acid

Strandedness; single

Topology; linear

Molecule type; other nucleic acids synthetic DNA

Sequence Description

TCGAGCCCCGG GGGTACCGCA TG

22

Sequence ID No.17

Length; 14

Type; nucleic acid

Strandedness; single

Topology; linear

Molecule type; other nucleic acids synthetic DNA

Sequence Description

CGGTACCCCC GGGC

14

Sequence ID No.18

Length; 60

Type; nucleic acid

Strandedness; single

Topology; linear

Molecule type; other nucleic acids synthetic DNA

Sequence Description

TCGAGCTTGG CGGGAAACTT GGC GGGGAAAC TTGGCGGGAA ACTTGGCGGG

AAAGTCGACG

60

Sequence ID No.19

Length; 60

Type; nucleic acid

Strandedness; single

Topology; linear

Molecule type; other nucleic acids synthetic DNA

Sequence Description

GTACCGTCGA CTTTCCCGCC AAGTTTCCCG CCAAGTTTCC CGCCAAGTTT

CCCGCCAAGC

60

Sequence ID No.20

Length; 29

Type; amino acid

Strandedness; single

Topology; linear

Molecule type; peptide

Sequence feature

Name/Key; Modified-site

Location; 1

Identification method of feature; E

Other information; Xaa at position 1 representing N-lauroyl-L-leucine

Name/Key; Modified-site

Location; 29

Identification method of feature; E

Other information; Xaa at position 29 representing L-alaninamide

Sequence Description

Xaa Asn Trp Ala Ala Glu Val Leu Lys Val Gln Lys Arg Arg Ile Tyr

1

5

10

15

Asp Ile Thr Asn Val Leu Glu Gly Ile Gln Leu Ile Xaa

20

25

Sequence ID No.21

Length; 28

Type; amino acid

Strandedness; single

Topology; linear

Molecule type; peptide

Sequence feature

Name/Key; Modified-site

Location; 1

Identification method of feature; E

Other information; Xaa at position 1 representing N-lauroyl-L-asparagine

Name/Key; Modified-site

Location; 28

Identification method of feature; E

Other information; Xaa at position 28 representing L-serinamide

Sequence Description

Xaa Glu Ser Ala Tyr Asp Gln Lys Asn Ile Arg Arg Arg Val Tyr Asp

1 5 10 15

Ala Leu Asn Val Leu Met Ala Met Asn Ile Ile Xaa

20 25


Claims

1. A compound represented by the general formula (I).




(wherein R^1 represents substituted or unsubstituted alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl or a hydrogen atom, R^2 represents hydroxy, substituted or unsubstituted alkoxy, or substituted or unsubstituted amino; and A represents a peptide sequence comprising a partial amino acid sequence having at least 12 continuous residues in the sequence of the dimerization region or DNA binding region of each E2F family), or a pharmaceutically acceptable salt thereof

2. A compound according to claim 1, wherein A is represented by the general formula (Ia).




(Ia)

(wherein "n's" in individual amino acid residues are the same or different, and represent 0 or 1, X^1 , X^3 , X^{27} and X^{28} are the same or different, representing Leu or Ile, X^2 represents Asn or Lys, X^3 represents Trp, Lys, Leu, Ala or Glu, X^5 represents Ala or Ser, X^6 represents Glu, Asp or Asn, X^7 represents Val, Thr or Arg, X^8 represents Lys, Asp, Ala or His, X^{26} represents Gln, His, Gly, Asp or Asn, and X^{29} represents Ala, Arg, Lys or Glu), or by the general formula (Ib),



(Ib)

(wherein "m's" in individual amino acid residues are the same or different, and represent 0 or 1, Y^1 represents Asn, Thr, Ala or Tyr, Y^2 represents Glu or Asp, Y^3 represents Ser or Asn, Y^5 represents Ala or Asn, Y^6 represents Tyr or Cys, Y^9 represents Lys or Glu, Y^{25} represents Met or Ile, and Y^{27} represents Ile or Val), or by the general formula (Ic),



(Ic)

(wherein 'p's' in individual amino acid residues are the same or different, and represent 0 or 1; Z^1 represents Ala, Phe or Pro; Z^2 represents Arg, Lys or Gln; Z^3 , Z^{11} and Z^{17} are the same or different, representing Gly or Pro; Z^4 represents Arg, Lys, Met or Pro; Z^5 represents Gly, Cys, Ala or Gln; Z^6 represents Ala, Arg or Glu; Z^7 represents Ala, Ile or Gln; Z^8 represents Ala, Gly or Arg; Z^9 represents Leu, Val or Pro; Z^{10} represents Asp, Arg or Gln; Z^{12} represents Gly, Ser, Ala or Pro; Z^{13} represents Leu or Pro; Z^{14} represents Asp, His or Pro; Z^{15} represents Ser or Pro; Z^{16} represents Gln or Lys; Z^{18} represents Gly, Thr or Leu; Z^{19} represents Gly, Pro or Val; Z^{20} represents Gly or Lys; Z^{21} represents Ala or Ser; Z^{22} represents Gly or Ser; Z^{23} represents Gly, Glu or Thr; Z^{24} represents Arg, Lys, Ser or Pro; Z^{25} represents Ser or Thr; Z^{26} represents His or Tyr; Z^{28} represents Asp or Glu; Z^{29} and Z^{35} are the same or different, representing Lys or Thr; Z^{30} represents Gly or Asn; Z^{34} represents Leu or Thr; Z^{37} represents Arg or Lys; Z^{39} represents Ile, Leu or Val; and Z^{40} represents Glu, Gln, Ser or Tyr), or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound represented by the general formula (I),



(wherein R^1 represents substituted or unsubstituted alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aryloxy carbonyl, substituted or unsubstituted heteroaryloxy carbonyl or a hydrogen atom; R^2 represents hydroxy, substituted or unsubstituted alkoxy, or substituted or unsubstituted amino; and A represents a peptide sequence comprising a partial amino acid sequence having at least 12 continuous residues in the sequence of the dimerization region or DNA binding region of each E2F family) or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP97/03442

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl ⁶ C07K14/47, A61K38/17		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Int. Cl ⁶ C07K14/47, A61K38/17		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
CAS ONLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
A	WEINBERG et al. "E2F-4 and E2F-5, two members of E2F family, are expressed in the early phases of the cell cycle", Proc. Natl. Acad. Sci., USA, (1995), Vol. 92, p. 2403-2407	1 - 3
P,A	BANDARA et al. "Apoptosis induced in mammalian cells by small peptides that functionally antagonize the Rb-regulated E2F transcription factor", Nat. Biotechnol., (1997), Vol. 15, No. 9, p.896-901	1 - 3
A	JP, 6-503966, A (Creative Biomolecules Inc.), May 12, 1994 (12. 05. 94), Claims & EP, 566673, A1 & WO, 92/11364, A1 & US, 5418135, A & AU, 648630, B	1 - 3
A	JP, 5-503529, A (Salk Inst. Biological Studies), June 10, 1993 (10. 06. 93), Claims & EP, 514475, A1 & US, 5064939, A & WO, 91/12013, A1 & AU, 639310, B & HU, 62015, T	1 - 3
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
December 16, 1997 (16. 12. 97)		December 24, 1997 (24. 12. 97)
Name and mailing address of the ISA		Authorized officer
Japanese Patent Office		
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

